Astra Zeneca COVID-19 vaccine
GPTKB entity
Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:accessories |
gptkb:COVAX_Facility
|
| gptkbp:approves |
gptkb:World_Health_Organization
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
over 30,000
global Phase III |
| gptkbp:communication |
public health campaigns ongoing
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
gptkb:battle
2 4 to 12 weeks |
| gptkbp:economic_impact |
contributed to global vaccination efforts
|
| gptkbp:emergency_services |
multiple countries
|
| gptkbp:has_variants |
reduced efficacy against some variants
|
| gptkbp:healthcare |
gptkb:significant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca COVID-19 vaccine
|
| gptkbp:is_effective_against |
approximately 76% after two doses
|
| gptkbp:is_vulnerable_to |
gptkb:Astra_Zeneca/_Oxford_vaccine
worldwide December 2020 ongoing varies by country limited in some regions logistical challenges in distribution continuing funded by various organizations non-replicating viral vector viral vector platform conducted in multiple phases addressed through education efforts adverse event monitoring in place collaboration with governments and NG Os equitable access initiatives high against severe disease may reduce transmission mixed in some regions rapid development due to pandemic |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
multiple countries
|
| gptkbp:marketed_as |
gptkb:Vaxzevria
|
| gptkbp:partnerships |
gptkb:Oxford_University
|
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:safety_features |
ongoing
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever thrombosis thrombocytopenia |
| gptkbp:storage |
less stringent than m RNA vaccines
|
| gptkbp:target_audience |
adults
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:technology |
recombinant DNA technology
|
| gptkbp:type |
viral vector vaccine
|